SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to regulation 39(3) of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we hereby inform you that share certificate(s) as per attached details, issued by Sun Pharma Advanced Research Company Limited, have been reported by the registered shareholder(s)/ bona fide purchasers to have been lost/ misplaced/stolen. Sun Pharma Advanced Research Company Ltd - 532872 - Shareholding for the Period Ended June 30, 2019
Sun Pharma Advanced Research Company Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2019. For more details, kindly Click here SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Board Meeting Intimation for Notice Of Board Meeting For Consideration Of Unaudited Financial Results Of The Company For The Quarter Ended 30Th June 2019
SUN PHARMA ADVANCED RESEARCH COMPANY LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2019 ,inter alia, to consider and approve Pursuant to regulation 29 (1) of the SEBI (Listing obligation & Disclosure Requirements) Regulation, 2015, we hereby inform you that a meeting of the Board of Directors of Sun Pharma Advanced Research Company Limited will be held on Monday, 29th July, 2019, inter alia, to consider and approve, the unaudited financial results of the Company for the quarter ended 30th June 2019. Further, kindly note that pursuant to the Company's Code of Conduct for Prevention of Insider Trading, the trading window for trading by designated persons, shall remain closed upto 48 hours after the declaration of unaudited financial results of the Company on 29th July 2019. Sun Pharma Advanced Research Company Ltd - 532872 - Statement Of Investor Complaints For The Quarter Ended June 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- DEBASHIS DEYDesignation :- Company Secretary and Compliance Officer SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Fixes Book Closure for AGM
Sun Pharma Advanced Research Company Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from July 20, 2019 to July 29, 2019 (both days inclusive) for the purpose of 14th Annual General Meeting (AGM) of the Company to be held on July 29, 2019. Sun Pharma Advanced Research Company Ltd - 532872 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Dear Sir/Madam, Pursuant to regulation 30 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we enclose herewith the Press Release on the above mentioned subject being released by the Company, which is self-explanatory. We request you to kindly take the same on record. Sun Pharma Advanced Research Company Ltd - 532872 - Reg. 34 (1) Annual Report
In compliance with the SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015 we are pleased to enclose herewith the Annual Report of the Company for the FY ended 31st March 2019 along Notice of 14th Annual General Meeting of the Company to be held on Monday, 29th July, 2019 at 09:45 A.M. at Vasvik Auditorium, Trivia Complex, Race Course Road, Gautam Nagar, Vadiwadi, Vadodara - 390007, Gujarat, India, with which is being dispatched to the members by the permitted modes. Further, pursuant to regulation 42 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015 we hereby inform you that the voting rights of shareholders shall be in proportion to their shares of the paid-up equity share capital of the Company as on the cut-off date of 20th July, 2019. For shareholders holding shares in physical mode, Register of Members and Share Transfer Books of the Company shall remain closed from 20th July, 2019 up to 29th July, 2019 (both days inclusive). Sun Pharma Advanced Research Company Ltd - 532872 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to regulation 39(3) of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we hereby inform you that the share certificate(s) as per attached details, issued by Sun Pharma Advanced Research Company Limited, have been reported by the registered shareholder(s)/ bona fide purchasers to have been lost/ misplaced/stolen. Sun Pharma Advanced Research Company Ltd - 532872 - Disclosure Of RPT Transactions Under Regulation 23(9) Of The SEBI (LODR), Regulations For The Half Year Ended March 31, 2019
In compliance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulations, 2018, we hereby submit the Related Party Transactions on consolidated basis, in accordance with the applicable accounting standards, for the half year ended March 31, 2019. Sun Pharma Advanced Research Company Ltd - 532872 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompaySUN PHARMA ADVANCED RESEARCH COMPANY LTD. 2CINL73100GJ2006PLC047837 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 2.50 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: DEBASHIS DEY Designation: COMPANY SECRETARY EmailId: debashis.dey@sparcmail.com Name of the Chief Financial Officer: CHETAN RAJPARA Designation: CFO EmailId: chetan.rajpara@sparcmail.com Date: 22/05/2019 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.